Skip to main content

Advertisement

Table 2 Patient characteristics at admission and univariate analysis of risk factors associated with mortality

From: Adjunctive steroid in HIV-negative patients with severe Pneumocystis pneumonia

Variable Survival patients n=103(75%) Dead patients n=36(25%) p value
Age in years, median [IQR] 46 [39–57] 52 [40–65] 0.15
Males, n (%) 61 (59.2) 18 (50) 0.34
SAPS II, median [IQR] 31 [23–41] 35 [30–51] 0.01
Underlying disease, n (%)    
   Hematological malignancy 68 (66.0) 16 (44.4)  
   Solid organ transplantation or immunological disease or cancer 35 (33.9) 20 (55.5) 0.02
PCP prophylaxis, n (%) 4 (3.8) 1 (2.7) 0.76
Steroids before admission, n (%) 53 (51.4) 21 (58.3) 0.48
Symptom duration in days, median [IQR] 7 [3-13] 7 [3-15] 0.71
Co infection at admission 20 (19.4) 8 (22.2) 0.66
P / F ratio at admission, median [IQR] 173 [96-268] 110 [86–197] 0.04
Mechanical ventilation, n (%)    
   None 53 (51.4) 2 (0.5)  
   NIV 25 (24.2) 1 (0.2) <0.001
   NIV and MV 25 (24.2) 33 (91.6)  
Shock during ICU stay, n (%) 19 (18.4) 26(72.2) <0.001
ICU acquired infection 14 (13.5) 17 (47.2) <0.0001
Steroids in the ICU, n (%)    
   No Steroid 33 (32.0) 12 (33.3)  
   Low Dose Steroid 19 (18.4) 3 (8.3) 0.60
   High Dose Steroids 51 (49.5) 21 (58.3)  
  1. IQR interquartile range, OR odds ratio, 95%CI 95% confidence interval, SAPS II, Simplified Acute Physiology Score, version II; PCP Pneumocystis pneumonia, NIV noninvasive ventilation, MV endotracheal mechanical ventilation, ICU intensive care unit, HDS high-dose steroid therapy, LDS low-dose steroid therapy, NS no steroid therapy.